Cortagen: Scientific Profile

Publicado el 12 de julio de 2026 · Actualizado el 28 de agosto de 2026

Cortagen (CAS 335591-03-2) is a synthetic tetrapeptide of sequence Ala-Glu-Asp-Pro (AEDP), classified among the short peptide bioregulators of the Khavinson school and originally associated with cerebral cortex extracts. For research use, it is studied as a model of regulation of gene expression and of nervous tissue regeneration processes. Its evidence is limited and comes mostly from a single research group and from preclinical models.

Cortagen is a synthetic tetrapeptide of the sequence Ala-Glu-Asp-Pro (abbreviated AEDP), with CAS number 335591-03-2, molecular formula C17H26N4O9, and a molecular weight of 430.41 g/mol. It belongs to the family of the so-called short peptide bioregulators developed by the group of Vladimir Khavinson and collaborators in St. Petersburg, a line of research that proposed that peptides of two to four amino acids, originally obtained by fractionation of animal organ extracts, could serve as tissue-specific regulators. In this scheme, each bioregulator is nominally associated with a tissue of origin: Cortagen derives its name from the cerebral cortex (from the Latin "cortex"), analogously to how other bioregulators of this family were historically linked to their tissue of origin. The synthetic version, such as the one described here, reproduces the peptide sequence without resorting to biological material, which facilitates its standardized use in research.

From a structural standpoint, Cortagen is a small, well-defined molecule: four residues (alanine, glutamic acid, aspartic acid, and proline) joined by conventional peptide bonds. The presence of two dicarboxylic amino acids (Glu and Asp) confers a markedly anionic character on the molecule at physiological pH, while the C-terminal proline residue introduces a conformational restriction characteristic of many short regulatory peptides. This combination of charge and local rigidity is the basis for the hypothesis, proposed by the original group, that these peptides could interact relatively selectively with DNA sequences or with chromatin-associated proteins.

The mechanism of action proposed for Cortagen and for the other short bioregulators lies in the field of the regulation of gene expression rather than in that of a classical surface receptor. The working hypothesis of the Khavinson group holds that these anionic tetrapeptides can penetrate the cell and the nucleus and interact with regions of DNA, modulating the transcription of certain genes and, consequently, the synthesis of proteins involved in differentiation, repair, and tissue homeostasis. It has been proposed, in in vitro models and in cell-free systems, that affinity for certain sequence motifs could explain a "tissue-oriented" action. It is important to emphasize that this mechanism remains to a large extent a hypothesis derived from a body of work concentrated in a single research environment, and that there is no robust independent mechanistic characterization nor a universally accepted molecular target. Consequently, any description of the mode of action should be read as a preliminary theoretical framework and not as an established mechanism.

The documented research applications for Cortagen have focused, within the original line, on the nervous system and on regeneration processes. In preclinical models it has been explored as a tool for studying the repair of peripheral nervous tissue, the neuronal response to experimental damage, and parameters of cortical plasticity and bioelectrical activity. Cortagen has also been included in broader experimental programs on tissue aging, in which the short bioregulators were used as probes to observe changes in cell proliferation and in differentiation markers. These applications define the compound's interest as a research reagent: a small peptide, synthetically accessible and of clear chemical identity, useful for modeling hypotheses about peptide gene regulation in cell cultures and animal models.

The level of evidence must be stated honestly. Most of the literature on Cortagen comes from a single research group and from publications concentrated within its circle, with little independent replication and no quality controlled clinical trials supporting therapeutic applications. It is not an approved drug nor a molecule with a regulatory dossier equivalent to that of peptides of established clinical classes. For this reason, Cortagen is classified here as a compound of limited evidence, appropriate exclusively as laboratory research material. The available data allow hypotheses to be formulated and experiments to be designed, but they do not support claims of clinical efficacy.

In practical terms for the laboratory, Cortagen is usually handled as a lyophilized powder that is reconstituted in a sterile aqueous vehicle to prepare working solutions. Its short-peptide character makes it sensitive to degradation by proteases and to freeze-thaw cycles, so storage and handling conditions are relevant for preserving the integrity of the molecule during studies. Being a defined sequence (AEDP), its identity can be confirmed by mass spectrometry and its purity by HPLC, which facilitates quality control in an experimental context. In summary, Cortagen is a synthetic tetrapeptide of the Khavinson bioregulator family, with a proposed mechanism centered on the regulation of gene expression, research applications oriented toward nervous tissue and regeneration, and a limited level of evidence that demands interpretive caution and a strictly research framework.